EPS we know is calculated on Total Earnings/Outstanding shares. The figures I quoted based on Thompson Reuters data out from the ASX were percentages. They stated that there was an % improvement increase on the financials. So, yes, you are correct that the company certainly was in the red to the tune of $6,753,359 with an EPS of (-$0.68) as seen in the recent EOFY report, compared to the previous financial year where there was a loss of $16,656,439, and an EPS of (-$2.01).
The EPS% has greatly improved from the previous year. So what exactly is your question???
You do say "it is unlikely to survive!" And yet we have just heard that NOR 'have received' an R&D grant of $924,091.82. We also know that they are still receiving continuing revenue from their clients with strict budgetary belt tightening controls presently in place.
Is NOR in its death rattles?? FACT: We know that with current financial controls in place, and with the help of the recent R&D tax grants that the immediate short term material uncertainty has now been dealt with which covers us for the end of this Fiscal year. So NO...for 2017.
NOR has 3 months of trading, and time to present the market with a large fish for the 2018 fiscal year. There is also a good chance that the market has simply been delayed in its response to the positive ANN's out from NOR, and the share price "could do" a re-adjust in the next 4 to 6 weeks. Time will tell.
(20min delay)